Jul 9, 2021 | Clinical Trials, Healthcare, Innovation, Medical Translation, Pharmaceuticals, Regulatory
On our most recent Coffee & Conversations podcast episode, podcast hosts Brigid and Shelby joined CSOFT’s President and CEO Shunee Yee and Professor Victoria Elegant, who serves as Vice-President of JAPAC Regional Medical Head of Amgen to discuss The Next...
Apr 15, 2021 | Clinical Trials, Health, Healthcare
Patient centricity and patient diversity are two trends that have taken the life science sector by storm. Simply put, patient centricity is defined as “designing a treatment, clinical trial, or other health solution centered around the patient”. Patient diversity, on...
Mar 5, 2021 | Clinical Trials, EMA, FDA, Health, Linguistic Validation, Medical Translation
Over the last several years, patient-centricity has been a key theme in the healthcare sphere for improving drug therapies and medical devices for patients all around the world. To better serve patients, life science companies are putting in more effort on listening...
Feb 18, 2021 | Clinical Trials, e-Learning, Health, Pharmaceuticals, Regulatory
There is no doubt that clinical trials are vitally important in the drug development process. As an increasing number of clinical trials are conducted overseas, sometimes with multiple ongoing studies at once, having in-depth knowledge...
Feb 3, 2021 | Clinical Trials, FDA, News, Regulatory
The U.S. Food and Drug Administration (FDA) has outlined an interim process for drug developers to relay any problems identified during record reviews instead of, or in advance of, preapproval inspections. Their responses will be taken into consideration before action...
Jan 7, 2021 | Clinical Trials, Health, Language Service Provider, Medical Translation, Pharmaceuticals, Regulatory
With a population of more than 1.3 billion people, India is one of the fastest growing economies in the world. As their global economy continues to expand, and as clinical trials are continuing to be conducted overseas, India remains unique in both the opportunities...
